Philips, Illumina to launch precision medicine cancer program with Navican

Royal Philips (NYSE:PHG) and Intermountain Healthcare company Navican inked an agreement today to launch a precision health informatics solution aimed at improving outcomes for late stage cancer patients.

The program is slated to leverage Navican‘s TheraMap Precision Cancer Care services and Philips’ IntelliSpace Genomics platform, which uses Illumina‘s next-gen genomic sequencing technologies.

At Utah-based Intermountain Healthcare’s Precision Genomics Laboratory, researchers analyze the genetic makeup of each patient’s cancer and a team of molecular tumor specialists and treatment navigators review the tests and determine how to most effectively proceed with treatment.

Get the full story at our sister site, Drug Delivery Business News.

The post Philips, Illumina to launch precision medicine cancer program with Navican appeared first on MassDevice.

from MassDevice http://ift.tt/2ssczqC